Specialist pharmaceutical company Shield Therapeutics has launched Feraccru (ferric maltol) within the UK to treat adults with iron deficiency anaemia (IDA) in patients affected with inflammatory bowel disease (IBD), who have previously failed on oral iron (ferrous) products.
The two primary forms of IBD include Crohn’s Disease and Ulcerative Colitis, while IDA is the most common non-intestinal symptom of IBD, affecting between 36% to 76% of patients.
Go deeper with GlobalData
Shield Therapeutics founder and chief executive officer Carl Sterritt said: "As part of our ongoing commitment to improve the lives of IDA patients with IBD, we are very pleased to report that they now have access to Feraccru in the UK.
"Based on the highly compelling results generated throughout its clinical trials, we believe that Feraccru is an exciting new oral treatment option for patients who have failed on oral ferrous products. These patients may previously have had to progress to IV iron or might have received no treatment at all.
"We would like to thank all the people who took part in our clinical trials, the investigators and everyone involved in bringing this important product to the market."
The symptoms of IDA, such as fatigue, in IBD patients can significantly affect their daily activities, including their ability to work.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFeraccru (ferric maltol), which is an effective oral ferric iron treatment for IDA, provides a new oral ferric alternative for adult IBD patients with IDA who have failed oral ferrous products.
Feraccru addresses an unmet need in IBD care and also serves as a well-tolerated oral alternative to intravenous (IV) iron in mild to moderate IBD patients.
Image: Micrograph showing inflammation of the large bowel in a case of inflammatory bowel disease. Photo: courtesy of Nephron.
